PREVAIL Trial Protocol: Early Intervention in Modifiable High-Risk COPD
- thuytienvuong
- Jun 3
- 2 min read
Our latest manuscript in the Journal of the COPD Foundation describes the protocol for PREVAIL, the first clinical trial to test whether much earlier intervention in patients at high-risk of COPD flare-ups reduces respiratory and cardiac events.
PREVAIL will evaluate the effectiveness of a novel quality improvement program (CONQUEST) that encourages the uptake of evidence and guideline-based strategies for the diagnosis and management of patients with modifiable high-risk COPD.
PREVAIL is currently being conducted in primary care settings in both the UK and US. In each country, patients with diagnosed, or potential undiagnosed COPD will be identified, who are at high risk of future respiratory and cardiac events and are not receiving optimal management in accordance with guidelines. These patients are described as ‘modifiable high-risk' .
Once identified, healthcare professionals receive clinical decision support, as part of the CONQUEST quality improvement program, to help them optimize the management of these patients.
PREVAIL will assess patient health outcomes over an average of two years, comparing results between primary care sites that did and did not receive the CONQUEST program, to determine whether the CONQUEST program is effective.
If found to be beneficial, the CONQUEST program could offer a scalable approach to improving the long-term health of people with modifiable high-risk COPD and provide learnings to healthcare professionals.
Read the full protocol manuscript here: “Pragmatic Evaluation of an Improvement Program for People Living with Modifiable High-Risk COPD versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial”
To learn more about the PREVAIL trial and the CONQUEST program, visit our websites:
The PREVAIL clinical trials are run by the Observational and Pragmatic Research International Limited (OPRI). This research and the development of the CONQUEST program is co-funded by Optimum Patient Care Global Limited and AstraZeneca.
